Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* on dialysis therapy for at least 12 weeks before screening;~* receiving darbepoetin alfa iv for at least 8 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of another investigational drug within 4 weeks before screening, or during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (1x/2 Weeks) (Type: EXPERIMENTAL): Eligible participants will be administered with RO0503821 (\[methoxy polyethylene glycol-epoetin beta\] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
- Darbepoetin (1x/1-2 Weeks) (Type: ACTIVE_COMPARATOR): Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).